COVID-19 Vaccine Development Tools Market - Global Industry Analysis

The global COVID-19 Vaccine Development Tools market accrued earnings worth approximately 15.5(USD Billion) in 2020 and is predicted to gain revenue of about 22.7(USD Billion) by 2028, is set to record a CAGR of nearly 8.7% over the period from 2021 to 2028. The report offers assessment and analysis of the COVID-19 Vaccine Development Tools market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Report Scope :

COVID-19 Vaccine Development Tools Market: Outlook

Development of vaccines for COVID-19 is a key for global economy to return to normalcy and hence various efforts & investments have been made by many countries for developing vaccines for offering protection to individuals against SARS-CoV-2 virus. According to NCBI, till March 2021, nearly 13 vaccines were approved for use and nearly more than 90 vaccines were undergoing phases of clinical trials. In addition to this, artificial intelligence and machine learning have proved to be effective tools in developing of COVID-19 vaccines. According to WHO, major components in vaccine development include antigens, residuals, preservatives, diluent, stabilizers, and surfactants and are manufactured by reputed pharma firms Pfizer, BioNTech, and Merck.

Furthermore, vaccine development can take many years of research before it can be approved for medical use by statutory (medical) authorities. Vaccine Inoculation for larger population becomes possible only after approval of vaccines. After development of new vaccine, it is tested in three phases. Phase I or preclinical phase includes testing of vaccines on animals and then on limited number of individuals to record or report stimulation of immune system due to vaccine injection. The Phase II testing includes vaccine inoculation in many persons involving old persons & children, thereby proving safety of vaccine inoculation in persons belonging to different age-groups. Final phase includes phase III clinical trials of vaccine performed on a large percentage of population. Apparently, these phase III clinical studies determine the effectiveness of vaccines against coronavirus without any side effects, thereby helping researchers in determining efficiency of vaccines. Based on success of Phase III trials, healthcare authorities decide on providing restricted approval for vaccines. After that, state officials review overall outcomes of clinical trials and based on that decide on fully approving production & use of vaccines.

COVID-19 Vaccine Development Tools Market: Growth Drivers

Increase in number of vaccine producers in both emerging economies and developed countries will boost growth of COVID-19 vaccine development tools market in upcoming years. Large-scale use of AI tools in development of COVID-19 vaccine and surge in strategic alliances & partnerships between various pharma firms facilitating intense research on vaccine development & production will enhance expansion of COVID-19 vaccine development tools industry in foreseeable future. Citing an instance, AstraZeneca entering into partnership with Serum Institute in India for developing Covishield Vaccine. Another instance is of Sanofi aiding production of COVID-19 vaccine by combined Pfizer-BioNtech firms through offering of services of bottle filling & packing for vaccines to latter. Favorable government legislations & incentives will prop up expansion of industry in years ahead.

Furthermore, need for avoiding COVID-19 vaccine manufacturing delays will promulgate growth of Covid-19 vaccine development tool market over forthcoming years. Enormous funding of research & development activities by private firms as well as government organizations for developing effective vaccines against COVID-19 for combating spread of COVID-19 pandemic along with reducing its intensity & effect through enhancing if human body immunity will steer market trends.

Regional Landscape

Asia Pacific To Contribute Major Market Share During 2021-2028

The expansion of COVID-19 vaccine development tools market in Asia Pacific during assessment period can be credited to prominent surge in vaccine development for COVID-19 in countries such as India, Israel, and China. Furthermore, determining of new COVID genome in initial stage through use of modern sequencing tools by researchers of sub-continent will expedite business landscape in Asia Pacific over ensuing years. Additionally, large-scale utilization of genome sequencing tools, viral structure examination tools, and immune response profiling systems for developing new vaccines against COVID-19 will steer regional industry trends.

Competitive Landscape

Key players profiled in study include Thermo Fisher Scientific, Inc., Pfizer Inc., Celerion, Sartorius AG,      Cole-Parmer Instrument Company, LLC, STEMCELL Technologies Inc., Illumina, Inc., AB Sciex Private Limited,  Agilent Technologies, Danaher Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., Merck KgaA, Shimadzu Corporation, PerkinElmer Inc., Eurofins Scientific, and Aurora Biomed Inc.

The global COVID-19 Vaccine Development Tools Market is segmented as follows:

By Technology

• Lab Technologies
• PCR & qPCR
• Flow Cytometry
• Spectrometry
• Electron Microscopy
• Next Generation Sequencing

By End-Use

• CROs
• Pharma & BioPharma Firms

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodulogy
    • 1.3.1. Market Research Type
    • 1.3.2. Market Research Methodulogy
• Chapter 2. Executive Summary
  • 2.1. COVID-19 Vaccine Development Touls Market, 2018–2028(USD Billion)
  • 2.2. COVID-19 Vaccine Development Touls Market: Snapshot
• Chapter 3. Global COVID-19 Vaccine Development Touls Market– End-Use Analysis
  • 3.1. COVID-19 Vaccine Development Touls Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Large-scale investment in research & development activities by private & government organizations for developing effective vaccines against COVID-19 will steer market trends.
    • 3.2.2. Humungous utility of AI touls in development of COVID-19 vaccine and surge in strategic alliances & partnerships between various pharma firms facilitating intense research on vaccine development & production will enhance expansion of COVID-19 vaccine development touls market in near future.
  • 3.3. Porter’s Five Forces Analysis
  • 3.4. Market Attractiveness Analysis
    • 3.4.1. Market attractiveness analysis By Technulogy
    • 3.4.2. Market attractiveness analysis By End-Use
• Chapter 4. Global COVID-19 Vaccine Development Touls Market– Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global COVID-19 Vaccine Development Touls Market: company market share, 2019
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Technulogy launches
    • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global COVID-19 Vaccine Development Touls Market– Technulogy Analysis
  • 5.1. Global COVID-19 Vaccine Development Touls Market overview: By Technulogy
    • 5.1.1. Global COVID-19 Vaccine Development Touls Market share, By Technulogy, 2020 and 2028
  • 5.2. Lab Technulogies
    • 5.2.1. Global COVID-19 Vaccine Development Touls Market by Lab Technulogies, 2018–2028(USD Billion)
  • 5.3. PCR & qPCR
    • 5.3.1. Global COVID-19 Vaccine Development Touls Market by PCR & qPCR, 2018–2028(USD Billion)
  • 5.4. Flow Cytometry
    • 5.4.1. Global COVID-19 Vaccine Development Touls Market by PCR & qPCR, 2018–2028(USD Billion)
  • 5.5. Spectrometry
    • 5.5.1. Global COVID-19 Vaccine Development Touls Market by Spectrometry, 2018–2028(USD Billion)
  • 5.6. Electron Microscopy
    • 5.6.1. Global COVID-19 Vaccine Development Touls Market by Electron Microscopy, 2018–2028(USD Billion)
  • 5.7. Next Generation Sequencing
    • 5.7.1. Global COVID-19 Vaccine Development Touls Market by Next Generation Sequencing, 2018–2028(USD Billion)
• Chapter 6. Global COVID-19 Vaccine Development Touls Market– End-Use Analysis
  • 6.1. Global COVID-19 Vaccine Development Touls Market overview: By End-Use
    • 6.1.1. Global COVID-19 Vaccine Development Touls Market share, By End-Use, 2020 and 2028
  • 6.2. CROs
    • 6.2.1. Global COVID-19 Vaccine Development Touls Market by CROs , 2018–2028(USD Billion)
  • 6.3. Pharma & BioPharma Firms
    • 6.3.1. Global COVID-19 Vaccine Development Touls Market by Pharma & BioPharma Firms, 2018–2028(USD Billion)
• Chapter 7. Company Profiles
  • 7.1. Thermo Fisher Scientific, Inc.
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Technulogy Portfulio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Pfizer Inc.
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Technulogy Portfulio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Celerion
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Technulogy Portfulio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Development
  • 7.4. Sartorius AG
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Technulogy Portfulio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Development
  • 7.5. Cule-Parmer Instrument Company, LLC
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Technulogy Portfulio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Development
  • 7.6. STEMCELL Technulogies Inc.
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Technulogy Portfulio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Development
  • 7.7. Illumina, Inc.
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Technulogy Portfulio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Development
  • 7.8. AB Sciex Private Limited
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Technulogy Portfulio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Development
  • 7.9. Agilent Technulogies
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Technulogy Portfulio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Development
  • 7.10. Aurora Biomed Inc.
    • 7.10.1. Overview
    • 7.10.2. Financials
    • 7.10.3. Technulogy Portfulio
    • 7.10.4. Business Strategy
    • 7.10.5. Recent Development
  • 7.11. Eurofins Scientific
    • 7.11.1. Overview
    • 7.11.2. Financials
    • 7.11.3. Technulogy Portfulio
    • 7.11.4. Business Strategy
    • 7.11.5. Recent Development
  • 7.12. PerkinElmer Inc.
    • 7.12.1. Overview
    • 7.12.2. Financials
    • 7.12.3. Technulogy Portfulio
    • 7.12.4. Business Strategy
    • 7.12.5. Recent Development
  • 7.13. Shimadzu Corporation
    • 7.13.1. Overview
    • 7.13.2. Financials
    • 7.13.3. Technulogy Portfulio
    • 7.13.4. Business Strategy
    • 7.13.5. Recent Development
  • 7.14. Merck KgaA
    • 7.14.1. Overview
    • 7.14.2. Financials
    • 7.14.3. Technulogy Portfulio
    • 7.14.4. Business Strategy
    • 7.14.5. Recent Development
  • 7.15. Qiagen N.V.
    • 7.15.1. Overview
    • 7.15.2. Financials
    • 7.15.3. Technulogy Portfulio
    • 7.15.4. Business Strategy
    • 7.15.5. Recent Development
  • 7.16. Bio-Rad Laboratories, Inc.
    • 7.16.1. Overview
    • 7.16.2. Financials
    • 7.16.3. Technulogy Portfulio
    • 7.16.4. Business Strategy
    • 7.16.5. Recent Development
  • 7.17. Danaher Corporation
    • 7.17.1. Overview
    • 7.17.2. Financials
    • 7.17.3. Technulogy Portfulio
    • 7.17.4. Business Strategy
    • 7.17.5. Recent Development